Professor Guy Pratt MD FRCP FRCPath

• MD (University of Cambridge)
• Fellow of the Royal College of Pathologists (FRCPath)
• Fellow of the Royal College of Physicians (FRCP)
• MBBChir (University of Cambridge)

Guy Pratt has been a Consultant Haematologist in Birmingham since 2001 with a clinical and research interest in Multiple Myeloma, Waldenstroms Macroglobulinaemia, plasma cell disorders such as amyloidosis and CLL. He trained at Cambridge University qualifying in 1989. Following junior doctor training in London he specialized as a specialist registrar in Haematology in Liverpool and Leeds. In Leeds he completed an MD thesis in Multiple Myeloma.

He was clinical lead for the 2016 NICE myeloma guidelines and had a number of previous positions nationally including BSH guideline lead for Haemato-Oncology, trustee for BSH, trustee for the charity WMUK, and chair of the BSH science and publication committee.

Over the years he has developed a large number of research collaborations including clinical trial involvement both locally and nationally on sverela trials as a co-investigator and is member of UK Myeloma trials group (UKMRA).

• Personal mentor for medical students.
• Lead an annual teaching module for the PIP module for second/third year medical students since 2012 entitled “Management of Haematological malignancies”.
• Lecture regularly to Haematology SpRs/juniors, on the MSc in Oncology, BMed Sci and BOP courses at the University and have regularly lectured to medical students, nurses and professions allied to medicine.

Guy supervises and co-supervises PhD students and academic clinical lecturers/fellows over a number of years.

Current Projects 

• Examining the tumour microenvironment in multiple myeloma and the premalignant MGUS including identifying metabolic changes and the effects of hypoxia on T cells and stromal cells with the aim of developing target therapies (Dr Sarah Dimeloe, Professor Dan Tennant, Professor Paul Moss). 
• The clinical utility of the mass spectrometry assay for measuring myeloma proteins in a range plasma cell disorders as a marker of disease and minimal residual disease (Binding Site UK Ltd, Birmingham, UK) (Professor Ashu Wechalekar).
• Understanding immunity to common infections and responses to vaccination in patients with plasma cell disorders (in the RADAR trial, Professor Kwee Yong, Professor Mark Drayson) and CLL (Dr Helen Parry, Professor Paul Moss).
• Detetction of myeloma proteins and assessment of immunity in saliva in patients with plasma cell diosrders (Professor Iain Chapple, Professor Mark Drayson).
• Understanding the metabolic changes in the transformation from MGUS to multiple myeloma (Professor Chris Bunce, Professor Mark Drayon, Dr Sarah Dimeloe, Professor Dan Tennant).
• Collaborations providing real world data for patients with myeloma, amyloidosis and Waldenstroms (UK wide looking at outcomes for patient groups and the impact of treatments).
• Develoment of a specialised tertiary centre for patients AL amyloidosis and monoclonal gammopathy of clinical significance (Dr Jenny Pinney, Dr Will Moody, Professor Yusuf Rajabally).

• Secretary for the British Society for Haematology
• Secretary for the UK Myeloma Society
• Trustee for the charity Cure Leukaemia
• Member of the UK Myeloma Research Alliance
• Member of International Myeloma Working Group
• Myeloma UK -patient charity (sit on a number of working groups for early diagnosis and MGUS, provide advocacy, educational input for patients and healthcare professionals) 
• Expert for the patient charity Waldenstroms UK (previous trustee involved in educational activities and supporting WMUK)